Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Offer Update

10 Aug 2009 07:00

RNS Number : 1322X
Celsis International PLC
10 August 2009
 



Not for release, publication or distribution in whole or in part in or into or from the United States, Canada, Australia or Japan or any other jurisdiction where it is unlawful to do so.

CELSIS INTERNATIONAL PLC ("Celsis")

Offer update - publication of Offer Document

Further to the announcement of the recommended cash offer by Nastor Investments Limited for Celsis International plc on 3 August 2009 (the "Offer"), the board of Celsis announces that the Offer Document relating to the Offer is today being posted to Celsis Shareholders. 

The first closing of the Offer is at 1.00 p.m. (London time) on 2 September 2009. To accept the Offer for Celsis Shares held in certificated form, Celsis Shareholders should complete, sign and return the Form of Acceptance, which accompanies the Offer Document, in accordance with the instructions contained therein and set out in the Offer Document.

 

To accept the Offer for Celsis Shares held in uncertificated form (that is, in CREST), Celsis Shareholders should follow the procedure for electronic acceptance through CREST in accordance with the instructions set out in the Offer Document. 

Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement dated 3 August 2009. 

In accordance with Rule 19.11 of the City Code, a copy of this announcement will be published on the following websites: www.navalue.co.uk/site/literature/NASTOR/ and www.celsis.com/about-our-company/news-room/financial-news/2009/. 

Copies of the Offer Document and Form of Acceptance will be available from the offices of Capita Registrars, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU. The Offer Document may also be obtained from the website of Celsis, www. celsis.com/about-our-company/news-room/financial-news/2009/.

For assistance relating to the Offer, please telephone Capita Registrars on 0871 664 0321 from within the UK or on + 44 20 8639 3399 if calling from outside the UK. Calls to the 0871 664 0321 number cost 10 pence per minute from a BT landline. Other network providers' costs may vary. Lines are open 9.00 am to 5.00 pm (London time) Monday to Friday (except UK public holidays). Calls to the helpline from outside the UK will be charged at the applicable international rate. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. The helpline cannot provide advice on the merits of the Proposals nor give any financial, legal or tax advice

PRESS ENQUIRIES

For further information contact:

Nastor Investments Limited

020 7747 5678

Jeremy Brade

Timothy Sturm

KBC Peel Hunt (Financial Adviser to Nastor Investments)

020 7418 8900

Richard Kauffer

Daniel Harris

Simon Brown

Celsis

020 7831 3113

Jay LeCoque

Christian Madrolle

Nomura Code (Financial Adviser to Celsis)

020 7776 1200

Chris Collins

Phil Walker

Giles Balleny

Financial Dynamics (PR Adviser to Celsis)

020 7831 3113

Jonathan Birt

Susan Quigley

KBC Peel Hunt Ltd ("KBC Peel Hunt") which is authorised and regulated by the Financial Services Authority in the United Kingdom, is acting for Nastor Investments and no one else in connection with the Offer and will not be responsible to any person other than Nastor Investments for providing the protections afforded to clients of KBC Peel Hunt or for providing advice in relation to the Offer, the content of this announcement or any matter referred to herein.

Nomura Code Securities Limited ("Nomura Code"), which is authorised and regulated by the Financial Services Authority in the United Kingdom, is acting for Celsis and no one else in connection with the Offer and will not be responsible to any person other than Celsis for providing the protections afforded to clients of Nomura Code or for providing advice in relation to the Offer, the content of this announcement or any matter referred to herein. 

 

This announcement does not constitute, or form part of, any offer for, or any solicitation of any offer for, securities. Any response to the Offer should be made only on the basis of information referred to in the Offer Document.

The availability of the Offer to persons who are not resident in the United Kingdom may be affected by the laws of the relevant jurisdiction in which they are located. Such persons should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdiction. Any failure to comply with these requirements may constitute a violation of the securities laws at any such jurisdiction. Further details in relation to overseas shareholders are contained in the Offer Document.

The Offer referred to in this announcement will not be made available directly or indirectly, in, into or by use of the mails of, or by any means or instrumentality (including, without limitation, telephonically or electronically) or interstate or foreign commerce of, or any facilities of a nationals securities exchange of, the United States, Canada, Australia or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. This announcement does not constitute an offer in the United States, Canada, Australia or Japan or any such other jurisdiction and the Offer will not be made available by any such use, means, instrumentality or facilities or otherwise from or within the United States, Canada, Australia or Japan or any such other jurisdiction. Accordingly this announcement is not being, and should not be, mailed, transmitted or otherwise distributed, in whole or in part, in or into or from the United States, Canada, Australia or Japan or any such other jurisdiction.

DEALING DISCLOSURE REQUIREMENTS

Under the provisions of Rule 8.3 of the Code, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Celsis, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Celsis, they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of Celsis by Nastor Investments or by any of its "associates", must be disclosed by not later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.

"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel on telephone number +44(0)20 7382 9062 or fax number +44(0)20 7638 1554.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPCKCKPDBKBNFK
Date   Source Headline
5th Jul 20073:18 pmRNSHolding(s) in Company
20th Jun 20077:00 amRNSFinal Results
16th May 20077:01 amRNSNotice of Results
15th May 20077:01 amRNSRe Appointments
19th Apr 20079:26 amRNSHolding(s) in Company
28th Mar 20077:01 amRNSTrading Update
20th Mar 200712:28 pmRNSHolding(s) in Company
16th Mar 20079:22 amRNSHolding(s) in Company
9th Mar 20078:00 amRNSHolding(s) in Company
6th Mar 200712:10 pmRNSHolding(s) in Company
5th Feb 20073:36 pmRNSHolding(s) in Company
1st Feb 20077:00 amRNSTotal Voting Rights
24th Jan 20077:01 amRNSTreasury Stock
15th Dec 20067:58 amRNSTotal Voting Rights
11th Dec 20065:41 pmRNSHolding(s) in Company
17th Nov 20067:00 amRNSDirector/PDMR Shareholding
8th Nov 20067:00 amRNSInterim Results
2nd Nov 20065:08 pmRNSHolding(s) in Company
25th Oct 20064:08 pmRNSNotice of Results
28th Sep 20067:00 amRNSPreClose Trading Update
19th Sep 20067:00 amRNSInVitro Technologies Inc
11th Sep 20064:34 pmRNSHolding(s) in Company
30th Aug 20064:38 pmRNSHolding(s) in Company
1st Aug 20065:09 pmRNSHolding(s) in Company
31st Jul 20064:47 pmRNSShare Options
26th Jul 20065:25 pmRNSResult of AGM
26th Jul 20067:01 amRNSAGM Statement
7th Jul 20064:55 pmRNSAnnual Information Update
7th Jul 20064:53 pmRNSAnnual Report and Accounts
16th Jun 20063:37 pmRNSDoc re: Acquisition
14th Jun 20067:01 amRNSAcquisition
14th Jun 20067:01 amRNSFinal Results
6th Jun 20063:13 pmRNSNotice of Results
28th Mar 20067:00 amRNSTrading Statement
10th Mar 200611:19 amRNSTreasury Stock
7th Mar 20063:58 pmRNSHolding(s) in Company
7th Mar 20063:56 pmRNSHolding(s) in Company
3rd Feb 20067:00 amRNSNew Contracts
1st Feb 200612:27 pmRNSHolding(s) in Company
30th Jan 20064:23 pmRNSHolding(s) in Company
14th Nov 20057:01 amRNSChange of Adviser
9th Nov 200510:53 amRNSHolding(s) in Company
8th Nov 20057:01 amRNSInterim Results
5th Oct 20057:00 amRNSNotice of Results
29th Sep 20057:00 amRNSTrading Statement
22nd Sep 20056:17 pmRNSTreasury Stock
22nd Sep 20057:03 amRNSRe Agreement
21st Sep 20057:00 amRNSDirector/PDMR Shareholding
30th Aug 200511:43 amRNSShare Consolidation
24th Aug 20054:22 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.